CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
John Donald MarraEugenio GalliSabrina GiammarcoElisabetta MetafuniGessica MinnellaFederica FossoSara MariettiSimona SicaFederica SoràPatrizia ChiusoloPublished in: European journal of haematology (2024)
While there is intense interest in the production of allogeneic CAR-T cells from umbilical cord units, little is known about the reactivity and persistence of CAR-T cells of umbilical origin. We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post-allogeneic hematopoietic stem cell transplantation. The patient achieved a rapid CAR-T expansion and durable remission presenting in good clinical conditions 6 months post-CAR-T infusion, without manifestations of graft-versus-host disease. The case report provides insight into the reactivity and persistence of CAR-T cells of umbilical origin, confirming the potential promise of allogeneic umbilical cord-derived CAR-T cells.
Keyphrases
- case report
- umbilical cord
- mesenchymal stem cells
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- cord blood
- multiple sclerosis
- stem cell transplantation
- acute myeloid leukemia
- bone marrow
- disease activity
- induced apoptosis
- low dose
- oxidative stress
- climate change
- risk assessment
- machine learning
- cell proliferation
- artificial intelligence
- cell therapy
- smoking cessation
- signaling pathway